Elevated baseline resting heart rate (RHR) is associated with an increased risk for incident atrial fibrillation (AF) in ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

FDA approves Johnson & Johnson's Varipulse for targeted atrial fibrillation treatment, enhancing precision and safety ...

More than six million Americans experience atrial fibrillation, or Afib, each year. Penn Stare Health Heart and Vascular is now offering a new, very focused and safe approach to treating Afib, ...

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...

Johnson & Johnson MedTech will enter the U.S. pulsed field ablation market following an FDA green light for its Varipulse ...

Boston Scientific Corp. resumed enrollment in the AVANT GUARD trial of the Farapulse pulse field ablation (PFA) system after a pause reported in October “to assess a few unanticipated observations.” ...

Irvine: Johnson & Johnson MedTech has announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE Platform ...

The technology is integrated with company’s electroanatomical mapping system, which helps guide operators during AF ablation.

During the festive season particularly Diwali in India people can be more susceptible to heart diseases including holiday ...

Johnson & Johnson MedTech has received the US Food and Drug Administration (FDA) approval for its VARIPULSE Platform to treat ...

"With a growing prevalence of atrial fibrillation around the world, innovative solutions are critical in expanding options for patients and helping electrophysiologists treat AFib effectively and ...